<DOC>
	<DOCNO>NCT01301729</DOCNO>
	<brief_summary>This single arm , open-label study evaluate efficacy safety Herceptin ( trastuzumab ) combination taxane first line therapy participant HER2-positive breast cancer relapse neoadjuvant adjuvant Herceptin treatment . Participants receive Herceptin ( load dose 4 mg/kg intravenously [ iv ] , 2 mg/kg iv weekly thereafter ) 6 3-week cycle either docetaxel ( 100 mg/m2 iv every 3 week ) paclitaxel ( 90 mg/m2 every week ) . Herceptin treatment continue disease progression unacceptable toxicity occur .</brief_summary>
	<brief_title>A Study Herceptin ( Trastuzumab ) Combination With Taxane Participants With HER2-Positive Breast Cancer Who Relapsed After ( Neo ) Adjuvant Herceptin Treatment</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Female participant , &gt; /= 18 year age Locally recurrent/metastatic breast cancer ( relapse supra infraclavicular lymph node regard metastatic disease ) HER2positive primary disease Participants must receive Herceptin adjuvant and/or neoadjuvant setting Relapsed breast cancer &gt; /= 6 month discontinue last drug Herceptin and/or chemotherapy adjuvant and/or neoadjuvant set HER2positive breast cancer Measurable disease accord RECIST 1.0 Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Maximum cumulative dose doxorubicin &lt; /= 360 mg/m2 epirubicin &lt; /= 720 mg/m2 prior anthracyclines At least 3 week prior surgery radiotherapy Pregnant breastfeed woman Previous chemotherapy metastatic breast cancer ( prior endocrine therapy till progressive disease allow ) Pleural effusion , ascites bone lesion manifestation disease Brain metastases Invasive malignancy metastatic breast cancer Inadequate bone marrow , hepatic renal function Prior treatment antiHER therapy ( neo ) adjuvant Herceptin</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>